All posts by

23Aug/21

Bristol-Myers Squibb (BMY) BLA for Orencia Accepted for Priority Review by FDA for aGvHD – StreetInsider.com

August 23, 2021Uncategorized

Bristol-Myers Squibb (BMY) BLA for Orencia Accepted for Priority Review by FDA for aGvHD StreetInsider.com

23Aug/21

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD) – Maryville Daily Times

August 23, 2021Uncategorized

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD) Maryville Daily Times

23Aug/21

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD) – Business Wire

August 23, 2021Uncategorized

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD) Business Wire

23Aug/21